(TheNewswire)
|
|||||||||
March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces that, further to its news release dated February 21, 2025, the Annual General and Special Meeting (the “ Meeting ”) for the year ended July 31, 2024 has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG (the “ Asset Acquisitions ”), as well as a proposed financing utilizing a draw-down subscription facility structure.
The Company applied to the Ontario Superior Court of Justice for an order under section 133(3) of the Canada Business Corporations Act permitting it to hold the Meeting by March 26, 2025. The application was approved on Wednesday, February 26, 2025.
The Notice of Meeting, Management Information Circular, Financial Statements Request Form, Form of Proxy and Voting Instruction Form (the “ Meeting Materials ”) have been mailed to shareholders and were posted on the Company’s profile on SEDAR+ at www.sedarplus.ca on February 24, 2025.
Shareholders of record as of January 31, 2025, are entitled to vote their shares of the Company at the Meeting. The Company encourages its shareholders to vote in advance of the Meeting using the instructions on the Voting Instruction Form or the Form of Proxy that will be mailed to them with the Meeting Materials. Shareholders are reminded that proxies must be received by 10 a.m. (EST) on March 24, 2025.
For more information, please contact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: 604-428-7050
Jacek Antas, Director
About Helix BioPharma Corp.
Helix BioPharma Corp. is an oncology company shaping a near future where today’s hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company innovates from strength to tackle cancer’s biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio- conjugates that score with precision against prevalent CEACAM6-expressing solid tumours. Its lead candidate, Tumour Defence Breaker TM L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumours, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today’s front-running anti-cancer therapies. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bi-specific ADCs targeting CEACAM6 in discovery. Helix is listed on the TSX under the symbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWB under the symbol “HBP0”.
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include statements regarding plans, goals, objectives, intentions and expectations with respect to the closing of the Asset Acquisitions, the proposed financing, the date of the court application and the date of the Meeting, the ability of the Company to obtain an order from the Ontario Superior Court of Justice to extend the Meeting, and the Company’s future business, operations, research and development. Forward-looking statements can further be identified by the use of forward-looking terminology such as “will”, “plans”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results. Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements are intended to provide information about management’s current plans and expectations regarding future operations and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release. The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including the risk factors discussed in the Company’s continuous disclosure record filed under the Company’s profile on SEDAR+ at www.sedarplus.ca from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required.
Copyright (c) 2025 TheNewswire - All rights reserved.
